REVIEW article
Front. Public Health
Sec. Life-Course Epidemiology and Social Inequalities in Health
Volume 13 - 2025 | doi: 10.3389/fpubh.2025.1520772
This article is part of the Research TopicEquity in Cancer Care: Mechanisms and Interventions for Enhanced AccessView all articles
Tearing down inequalities in the healthcare system across Europe: the BEACON project
Provisionally accepted- 1Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology (IEO), Milano, Lombardy, Italy
- 2Applied Research Division for Cognitive and Psychological Science, European Institute of Oncology (IEO), Milan, Lombardy, Italy
- 3Department of Oncology and Hematology Oncology, Faculty of Medicine and Surgery, University of Milan, Milan, Lombardy, Italy
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Equity in healthcare remains a pressing issue in cancer care across the European Union. Although numerous European initiatives address prevention, early diagnosis, and treatment, significant disparities in access to innovative cancer therapies persist. Time-to-reimbursement for new anticancer drugs varies widely between member states, depending on national health policies, economic capacity, and healthcare infrastructure. These differences particularly affect countries in Central and Eastern Europe, where delays in reimbursement, limited access to clinical trials, and restricted availability of specialized care contribute to worse outcomes. This narrative review examines how disparities in reimbursement timelines and access to new cancer therapies may affect factors such as early detection, specialized treatment availability, clinical trial participation, and socioeconomic status. The discussion is framed within the BEACON project, a European Union-funded initiative under the EU4Health programme. BEACON brings together patients, healthcare providers, researchers, and policymakers to create a cross-border network for quality-assured diagnosis and treatment. Through its multilingual digital platform, the project fosters collaboration, supports health literacy, and enhances access to innovative cancer therapies, aiming to reduce inequities regardless of geographic or socioeconomic background.
Keywords: Cancer, Health Disparities, Survival, new therapies, New treatment, time to reimbursement Europe, Socioeconomic status
Received: 31 Oct 2024; Accepted: 19 May 2025.
Copyright: © 2025 Koukoutzeli, Ferraris, Coppini, Ferrari, Fragale, Trapani, MINCHELLA, Grasso, Curigliano and Pravettoni. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Chrysanthi Koukoutzeli, Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology (IEO), Milano, 20141, Lombardy, Italy
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.